CytomX Therapeutics Set to Present at December Conferences
CytomX Therapeutics, Inc. (NASDAQ: CTMX), a pioneering company in the field of masked, conditionally activated biologics, is gearing up for a significant presence at investor conferences this December. Management is excited to participate in two prominent conferences, offering insights into their innovative approaches in oncology.
Details of the Upcoming Conferences
8th Annual Evercore Healthcare Conference
This conference will take place on Tuesday, December 2, 2025. CytomX management is scheduled for a fireside chat at 1:45 p.m. ET, where they will share the latest developments and future directions of the company.
Piper Sandler 37th Annual Healthcare Conference
On Thursday, December 4, 2025, CytomX will participate in the Piper Sandler conference, with a fireside chat set for 1:00 p.m. ET. This event provides a unique opportunity for attendees to learn more about CytomX’s advancements and future goals.
Live Webcasts and One-on-One Meetings
Those interested in following the developments at CytomX can view a live webcast of the presentation, which will be available on the company's Events and Presentations page. Furthermore, management will conduct one-on-one meetings with investors registered to attend these conferences, fostering direct engagement and discussion.
About CytomX Therapeutics
CytomX Therapeutics is at the forefront of developing innovative cancer therapies through its unique PROBODY therapeutic platform, which focuses on creating conditionally activated, masked biologics. This approach is designed to deliver targeted therapies directly to the tumor microenvironment, enhancing safety and efficacy in cancer treatment.
The company’s multi-modal technology has yielded a range of therapeutic candidates, such as antibody-drug conjugates (ADCs) and T-cell engagers. In its clinical-stage pipeline, CytomX has notable candidates like CX-2051 and CX-801. CX-2051 is specifically directed towards epithelial cell adhesion molecule (EpCAM), potentially applicable across various epithelial malignancies, while CX-801 is a masked interferon alpha-2b PROBODY cytokine designed for use in both sensitive and traditionally difficult-to-treat tumors.
Strategic Collaborations
CytomX has secured strategic partnerships with key players in the oncology field, including Amgen, Astellas, and Bristol Myers Squibb. These collaborations enhance the company’s capabilities in delivering innovative therapies to patients and position CytomX as a leader in the fight against cancer.
Contact Information
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
Frequently Asked Questions
What is the significance of CytomX participating in these conferences?
Participation in these conferences allows CytomX to showcase its innovative approaches and keep investors informed about the company’s advancements in cancer treatment.
How can investors access the live presentation?
The live presentation can be accessed via the Events and Presentations page on CytomX's official website.
What are the main products in CytomX's pipeline?
CytomX's pipeline includes promising candidates like CX-2051 and CX-801, focusing on targeted treatments for various types of cancer.
Who are some of CytomX's strategic partners?
CytomX has collaborated with leading oncology firms such as Amgen and Bristol Myers Squibb to enhance its research and development efforts.
How does CytomX's technology improve cancer treatment?
CytomX's PROBODY platform allows for tumor-targeted therapies that minimize damage to healthy tissues, offering a safer and more effective treatment option.
